Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.101,01
0,32%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ IN8bio Inc (INAB) IN8bio Inc (INAB) Notizie

IN8bio Inc

INAB
0,3282
0,0082 (2,56%)
23 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12/11/202422:45EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
12/11/202422:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:26GLOBEIN8bio Reports Third Quarter 2024 Financial Results and..
12/11/202413:00GLOBEIN8bio Announces Plenary Oral Presentation at the 2024..
05/11/202415:00GLOBEIN8bio Announces Upcoming Presentation at the 2024 American..
04/11/202422:31EDGAR2Form S-3 - Registration statement under Securities Act of..
12/10/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/10/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/10/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/10/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/10/202422:59EDGAR2Form 8-K - Current report
01/10/202414:00GLOBEIN8bio Announces Pricing of $12.4 Million Private Placement
11/9/202422:01EDGAR2Form 8-K - Current report
06/9/202422:05EDGAR2Form 8-K - Current report
05/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202422:18EDGAR2Form 8-K - Current report
04/9/202422:01GLOBEIN8bio Announces Clinical Pipeline Prioritization to Focus..
29/8/202412:05GLOBEIN8bio to Present at the H.C. Wainwright 26th Annual Global..
12/8/202423:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/8/202414:30EDGAR2Form 8-K - Current report
12/8/202414:05GLOBEIN8bio Solidifies Position as a Clinical Leader of..
08/8/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:08EDGAR2Form 8-K - Current report
08/8/202422:05GLOBEIN8bio Reports Second Quarter 2024 Financial Results and..
24/6/202414:00GLOBEIN8bio to Present at the H.C. Wainwright 2nd Annual Immune..
14/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202422:07EDGAR2Form 8-K - Current report
13/6/202422:01GLOBEIN8bio Presents Positive Data Demonstrating Durable 1-year..
03/6/202414:53EDGAR2Form 8-K - Current report
03/6/202412:05GLOBEIN8bio Presents Progression-Free Survival Update from Phase..
24/5/202414:00GLOBEIN8bio to Present at International Society for Cell & Gene..
23/5/202423:00GLOBEIN8bio Announces INB-200 Phase 1 Study Data in Newly..
14/5/202416:00GLOBEIN8bio Announces Upcoming Presentation at 2024 European..
13/5/202414:00GLOBEIN8bio Demonstrates Robust and Reproducible Gamma-Delta T..
09/5/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:04EDGAR2Form 8-K - Current report
09/5/202422:00GLOBEIN8bio Reports First Quarter 2024 Financial Results and..
07/5/202422:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/4/202412:05GLOBEIN8bio Doses First Patient in Phase 2 Clinical Trial of..
24/4/202414:00GLOBEIN8bio Announces Oral Presentation at the Upcoming American..
16/4/202422:05GLOBEIN8bio to Present at Noble Capital Markets Emerging Growth..
09/4/202422:30GLOBEIN8bio Announces New Preclinical Data for Gamma-Delta..
Apertura: 0,32 Min: 0,3107 Max: 0,327
Chiusura: 0,32

La tua Cronologia

NASDAQ
INAB
IN8bio
TSX
IVQ
Invesque
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network